Trevena to Present at the 21st Annual BIO CEO & Investor Conference
February 05 2019 - 6:58PM
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on
the development and commercialization of new and innovative
treatment options for patients in pain, today announced it will be
featured as a presenting company at the 21st Annual BIO CEO &
Investor Conference, sponsored by the Biotechnology Innovation
Organization (BIO), on Tuesday, February 12, 2019 in New York, NY.
Event: 21st Annual BIO CEO & Investor
Conference, sponsored by BIODate: Tuesday,
February 12, 2019Time: 9:15 a.m.
ESTLocation: Hudson/Empire meeting rooms, New York
Marriott Marquis, New York, NY
To join a live audio webcast of the presentation, please visit
the Investor section of the Company’s website. Following the
conclusion of the presentation, the webcast will be available for
replay for 30 days.
About TrevenaTrevena, Inc. is a
biopharmaceutical company focused on the development and
commercialization of new and innovative treatment options for
patients in pain. The Company has three novel and differentiated
investigational drug candidates, including IV oliceridine, for the
management of moderate to severe acute pain in hospitals, TRV250
for the treatment of acute migraine, and TRV734 for pain and/or
management of opioid dependence. In its preclinical programs,
Trevena is evaluating a set of novel S1P receptor modulators that
may offer a new, non-opioid approach to managing chronic pain.
ContactsBob YoderSenior Vice President and
Chief Business Officer610-354-8840Trevena,
Inc.
Investors:
ir@trevena.comorMedia:pr@trevena.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024